Recently, Sanyou Biopharmaceuticals Co., Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a subsidiary of Huadong Medicine Co., Ltd., have forged a powerful collaboration through the signing of a license agreement for a collaboratively developed therapeutic biological product. This license builds upon the strategic partnership agreement signed between the two parties back in November of 2020. As a cutting-edge biotechnology enterprise dedicated to the R&D and services of innovative biopharmaceuticals, Sanyou has established a world-leading technology platform, along with a ‘super-trillion innovative biologics discovery platform’.
Huadong Medicine, on the other hand, is an innovative international pharmaceutical company driven by scientific R&D and technology, and has deep expertise and insights in oncology. By leveraging each party’s strengths, they strive to make advances in the field of innovative biopharmaceuticals. Together, both Sanyou and Huadong Medicine can create powerful solutions to make a difference.
Dr. Jeffery Liu, Chief Scientific Officer of Huadong Medicine, expressed his delight in deepening the partnership with Sanyou through the mutually agreed upon innovation in the therapeutic area of oncology. “We are delighted to further collaborate with Sanyou, as this agreement marks an important milestone in our R&D investments,” he shared. Dr. Guojun Lang, CEO of Sanyou, echoed similar sentiments in honoring the strategic partnership.
“As an international pharmaceutical company, Huadong Medicine has been committed to strengthening its innovation and influence in the therapeutic area of oncology and has solid strength in transforming innovative projects into commercialized leading drugs,” he stated. “We hope that this project can progress into clinical stages in the near future, benefitting patients in need.” Sanyou is committed to its utmost efforts in supporting its partners in getting the innovative drug candidate into the clinical stages.
Huadong Medicine Co. Ltd., a twenty-year-old pharmaceutical giant, is a pioneering enterprise with its headquarters located in Hangzhou, China. Their success lies in adopting the “Science Driven, Patient Centered” approach, developing a comprehensive industry chain that unites pharmaceutical R&D, manufacturing and distribution. In 2021, Huadong Medicine witnessed an astounding annual revenue of 37.715 billion yuan.
Now one of the largest enterprises in this sector, the company boasts a workforce of ten thousand and exceptional marketing abilities. And to further their reach, they have collaborated with Sanyou Biopharmaceuticals Co. Ltd., which specializes in the research, production and supply of innovational biological drugs. Together they are striving to make it easier to discover life-changing treatments.
Sanyou has established an innovative and integrated research and development laboratory with advanced facilities, covering an area of 20,000 square meters. Our laboratory has created three industry-leading technology platforms characterized by “super-trillion, integration, and intelligence”, encompassing more than 50 sub-platforms, with the super-trillion phage display platform at its core.
Moreover, Sanyou’s platform and technology are continuously optimized with frequent upgrades and new versions for services and technologies, guaranteeing its innovation, outstandingness and reliability. We proudly boast a fruitful collaboration with over 1,000 pharmaceutical companies, drug R&D institutions, and diagnostics companies worldwide!